Table 1 Sociodemographic characteristics for placebo and ketamine interventions.

From: EEG-vigilance regulation is associated with and predicts ketamine response in major depressive disorder

 

Placebo

Ketamine

Clinical outcome 24 h after infusion (n)

Responders (1)a

Non-responders (23)

Responders (12)a

Non-responders (12)

Sex (M/F)

0/1

7/16

3/9

4/8

Age (Mean ± SD)

56

43.1 ± 12.5

42.6 ± 14.7

44.8 ± 10.3

Pretreatment MADRS

38

26.8 ± 4.2

27.6 ± 5.8

27.1 ± 3.9

24 h MADRS

19

27.4 ± 4.9

17.4 ± 7.5b

25.1 ± 4.0

ΔMADRS (% changes from 24 h to pretreatment)

50%

-2.5% ± 10.0%

35.1% ± 28%b

7.2% ± 10.0%

  1. MADRS Montgomery–Åsberg Depression Rating Scale.
  2. aResponders were defined by at least 30% improvement of depressive symptoms assessed by MADRS score after 24 h after interventions.
  3. bBetween group comparisons only performed for the ketamine intervention. The results showed that responders to ketamine had significant lower MADRS score 24 h after infusion compared to non-responders (F(1,22) = 9.80, p = 0.005); responders to ketamine had significant higher improvement on MADRS score 24 h after infusion compared to non-responders (F(1,22) = 10.63, p = 0.004). No significant was found for other demographic characteristics (p values > 0.65).
Back to article page